||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Verona Pharma Share Discussion Threads
Showing 12626 to 12650 of 12650 messages
|Timbo, I couldn't go either. I was looking forward to your write up. The 3 year EIS lock-in is over but trading is thin. I guess the 150p (3p in old money)level is going to be a key indicator on sentiment|
|Timbo,I attended the AGM, it was mentioned that the real money was in PDI &MDI and when Verona were in talks with the Chinese they wanted to see a hand held device. Which Verona are I the process of looking at. Could this have any bearing on things ?|
|Thanks for spotting that Kwizza
I have fixed the main link to Verona's web site, although I see that there are also a few others (on the Verona web site) which now need updating, I have rectified a couple of them and will look at the rest when I have a bit more time later this week.|
|timbo, the link to Verona website above is not working, could you have a look|
|I couldn't make it to the AGM this year (I had it down in my diary for the day before), but I look forward to seeing the AGM slides on the web site.
Today's announcement has me a bit puzzled
With the IND effective, the Company plans to initiate a PK clinical trial in the middle of this year in approximately 12 healthy volunteers to determine the oral bioavailability of RPL554, as well as assess the safety and tolerability of the drug. Top-line data is expected in the fourth quarter of 2017.
Are Verona considering developing an oral dosage form?|
|...not looking so good today?|
|VRP true to their word (not usual for AIM). All the makings for the offer being oversubscribed too.|
The strategy is clearer now in my view after today's announcement. Verona are clearly prepared to 'go it alone' - all the way if necessary and subject to funds. Thus the new collaborations to develop a DPI and MDI rather than any partnering with a big pharma who would no doubt want a deal on their own terms. In addition, bringing in Richard Hennings as the new Commercial Director seems to be linked with this strategy and brings more focus to Verona's own objectives.
If all goes well then with current and future trials, I personally see Verona sticking to their own devices and formulations either as a stand alone company or one that is eventually bought out 'off the peg' so to speak and the offerings would then simply become part of a larger pharma's portfolio of offerings under the Verona 'brand'.
All this of course does depend on the success of RPL554 in various trials. But I assume the new Commercial Director heard enough positives from our CEO to convince him to come on board at this stage. After all, this appointment is very different from the glut of NEDs appointed to the board who are mostly there on behalf of certain major investors.|
I assume they are both private companies (one for DPI and one for MDI) hence no need for them to be named or to announce themselves.
I am a bit disappointed with today's news as the original plan (last year) was to partner mdi and dpi formats with a big pharma and big pharma to pay for the development, so this suggests to me that they still have no takers (at the right price).
If they do end up getting a big pharma partner the work will have to be repeated using the partner's device and formulation.|
|Pity they do not say who the collaborations on DPI and MDI are with.|
|Todays RNS another step forward...|
|Annual report now published
The AGM will be held on April 12th starting at 12:00, I plan to attend|
|Very interesting Tim and it looks like a change in strategy by AZ in disposing of the US rights of these aclidinium based treatments. As recently as November 2014 AZ made this statement in relation to Duaklir when they obtained EC marketing authorisation -
'The EU approval of Duaklir Genuair marks an important further step in AstraZeneca's inhaled therapy strategy of providing physicians and patients a choice of products uniquely available in both dry powder and pressurised metered dose devices.'
Why keep the EC rights yet give up the US rights? And Circassia propose to double their salesforce to promote Tudorza - so clearly they think that it's worth sinking money into promoting Tudorza whereas presumably AZ do not. I suspect that there's more to this than meets the eye as to the deal itself and the enhanced relationship between AZ and Circassia.
Still, the deal once again raises the question as to what price the EU and US rights for a novel treatment such as RPL554 - which to date has not shown the side effects of aclidinium based medicines - might bring at some point in the future.|
|AN interesting announcement today from Circassia. I'm not sure what's in it for AZ. I guess they may think they have more than enough irons in the fire with their respiratory development portfolio
|Timbo............and do you feel if it is marketed as a combo we would get any significant returns on share price bearing in mind the royalties also due to vernalis????????.Remember at old money 5p JAK said significant shareholder value. That in new money is £2.50 so would expect £5 to £7.50 and as a combo cannot see it. I would like your reasoning if you see the share price going to this. I do not and I personally am very disappointed but likelihood it is the best that we can expect under the current management and with the absence of any clinical leadership with Kathy now at GSK.|
shakin not stirred
|Agreed Tim. I think Verona will also adopt the same approach if the current trial for RPL554 in CF patients goes well. Current inhaled steroid treatments as stated on the CF Trust website -
'The most commonly-used inhaled steroids are beclometasone (Becotide, Clenil, QVAR) and budesonide (Pulmicort), which both come as beige and brown inhalers, and fluticasone (Flixotide), which is an orange inhaler.
Sometimes, steroids are combined in the same inhaler with a long-acting medicine that helps relax the muscles of the airways. These are Seretide (fluticasone plus salmeterol), which is a purple inhaler, or Symbicort (budesonide plus formoterol), which is a white turbohaler with a red base.'
So I would also expect a Phase 2 combo trial for CF down the line all being well.|
|>>>>>the bossman, I doubt if there will ever be widespread use of RPL554 as a replacement for salbutamol or ipratropium, more likely it will be used in addition to Salbutamol and ipratropium and hopefully (eventually) it will be marketed as a combo. That would be good enough for me!|
|I'm amazed Piers ~Morgan has enough free time to take on an additional role given his busy schedule.|
|I like this bit of info stands out...
When RPL554 was added to each of salbutamol or ipratropium bromide it caused a significant reduction (p=0.0002 and p=0.004 respectively) in trapped air in the lung (residual volume) as compared to salbutamol or ipratropium bromide alone, suggesting that RPL554 treatment may reduce dyspnea, a major debilitating symptom of COPD...
So maybe 554 can be used instead of salbutamol or ipratropium a nice little earner me thinks...
Also a few bob in the bank..
Net cash used in operating activities during the year of £5.59m (2015: £6.36m) reflecting clinical progress, with cash and cash equivalents as at 31 December, 2016 increasing to £39.79m (2015: £3.52m).|
|Excellent clinical summary in today's results of the NEW formulation - which is what has attracted the new institutional investors.
We have both statistically significant results at Phase 2 when used as part of a combo plus excellent safety profile, wide dosage range, longevity of effects in the lungs and the 'gold standard' of twice daily dosing.
RPL554 - in its new formulation - is clearly becoming a potentially very valuable clinical asset.|
|From this mornings RNS it looks like we are onto a winner..|
|Unless you bought in at a penny in which case showing a profit.|
shakin not stirred
|I am waiting to see if Nasdaq listing makes a difference but need to get to £2 new money to break even. Will bale out when that is reached. Unless anything materially changes as to indicating a good news flow. At the moment it is a Jam tomorrow as have been the last few years for me and longer for others. None of us have invested in companys for F.A. but that is the current return at this moment in time. That is the current reality of the share price.|
shakin not stirred